Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
نویسندگان
چکیده
منابع مشابه
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
aECCO Governing Board; IBD Center, Humanitas Research Hospital, Rozzano, Milan,Italy bDepartment of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy cGuiCom Member; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy dY-ECCO; Department of Medicine, University of Cambridge, Cambridge, UK eCO ClinCom; Department of Gastroenterology, UZ Leuven, Leuven, Belgium fN-ECCO; ...
متن کاملUse of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market. This will most likely lead to decreased drug costs and so easier access to these expensive agents. Extrapolation, however, of the limited available clinical data from adults with rheumatologic diseases to children with inflammatory bowel disease (IBD) should be done wi...
متن کاملUse of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the management of inflammatory bowel disease in those cases which are refractory to conventional treatment; however these drugs are not risk-free and their use has substantially increased the cost of treatment. As marketing protection expires for original, first-generation biopharmaceuticals, lower-cost ...
متن کاملChallenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
In this article we discuss the challenges of delivering a high quality Transition care. A good understanding of the adolescent needs with good communication between Transition care physicians and the patient is essential for good continuity of care. Despite availability of several guidelines, one model doesn't fit all and any transition service development should be determined by the local need...
متن کاملThe Role of Biosimilars in Inflammatory Bowel Disease.
Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the most effective agents available. As the first of these biologic agents starts to come off patent, biosimilar agents have emerged as alternatives to originator drugs. The unique drug development and manufacturing processes in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Canadian Association of Gastroenterology
سال: 2020
ISSN: 2515-2084,2515-2092
DOI: 10.1093/jcag/gwaa004